Dyadic Q1 2025 revenue $394K, net loss $2.028M; cash $7.3M; progress on C1 platform grants

DYADIC INTERNATIONAL INC

2026-Q1 EPS reported -$0.07 vs consensus -$0.04 ▼ miss (-71.6%)

Revenue $394K, up from $335K YoY, driven by $210K in Gates Foundation and CEPI grant revenue.
Net loss $2.028M vs $2.01M YoY; operating loss improved to $2.002M from $2.126M.
Cash, cash equivalents and securities $7.3M at March 31, 2025, down from $9.3M at Dec 31, 2024.
Up to $4.5M CEPI grant and $3M Gates Foundation grant advancing C1 platform for vaccines and antibodies.
Commercial launch of recombinant Human Serum Albumin expected Q3 2025; dairy enzyme launch late 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.